Similarly, another clinical trial reported that combination treatment with atezolizumab, bevacizumab, and carboplatin/pemetrexed was associated with promising efficacy in metastatic EGFR-mutant NSCLC patients after EGFR-TKI failure [114]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.